Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1522

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 16
Chunk 1522
---
 Accounting Oversight Board (United States) (PCAOB) and are required to be independent
with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ Wolf & Company, P.C.

We have served as the Company's auditor since 2024.

Boston, MA

April 15, 2025

F-2

CERO THERAPEUTICS HOLDINGS, INC.

CONSOLIDATED
BALANCE SHEETS

    December 31,  
    December 31, 

    2024
 (Successor)  
    2023
 (Predecessor) 
  
    ASSETS 

    Current assets: 

    Cash, restricted cash, and cash equivalents 
    $3,327,060  
    $1,601,255 
  
    Prepaid expenses and other current assets 
     274,749  
     368,780 
  
    Deferred offering costs 
     112,232  
     - 
  
    Total current assets 
     3,714,041  
     1,970,035 

    Deferred offering costs, net of current portion 
     500,000  
     - 
  
    Operating lease right-of-use assets 
     1,464